Halozyme Therapeutics announced that a subcutaneous formulation of trastuzumab created with Halozyme’s technology, for the treatment of breast cancer, has received approval from Health Canada.
The California Department of Insurance has sued AbbVie for allegedly providing monetary gifts to health-care providers for prescribing its biologic, Humira.
A Highly Specialised Technologies programme will evaluate increasingly niche and expensive biologics and gene therapies like Glybera, says NICE as it publishes guidance recommending the funding of Alexion’s Soliris.